<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039858</url>
  </required_header>
  <id_info>
    <org_study_id>ARG-401</org_study_id>
    <secondary_id>SKF105043/013</secondary_id>
    <nct_id>NCT00039858</nct_id>
  </id_info>
  <brief_title>Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin</brief_title>
  <official_title>Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Encysive Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Encysive Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safe and effective dose of Argatroban for&#xD;
      prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous&#xD;
      diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who&#xD;
      in the opinion of the investigator require alternative anticoagulation due to an underlying&#xD;
      condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Thrombosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for Inclusion:&#xD;
&#xD;
          -  Males and females ages birth to 16 years,inclusive, at enrollment. For neonates, the&#xD;
             minimum corrected gestational age should be 37 weeks.&#xD;
&#xD;
          -  Documented HIT defined as a fall in platelet count to less than 100,000/uL or a &gt;=50%&#xD;
             decrease in platelets after the initiation of heparin therapy with no apparent&#xD;
             explanation other than HIT, or&#xD;
&#xD;
          -  Require anticoagulation and have a documented history of a positive HIT test in the&#xD;
             absence of current thrombocytopenia (i.e. patients at risk for HIT), or&#xD;
&#xD;
          -  In the opinion of the investigator, require alternative anticoagulation due to an&#xD;
             underlying condition, such as AT-III deficiency or heparin resistance.&#xD;
&#xD;
          -  Signed (written) informed consent or assent by the patient (if age appropriate) and&#xD;
             the patient's parent or guardian.&#xD;
&#xD;
        Criteria for Exclusion:&#xD;
&#xD;
          -  Any condition which, in the investigator's opinion, would contraindicate the use of&#xD;
             Argatroban or would endanger the patient if he/she participated in this trial.&#xD;
&#xD;
          -  Unexplained aPTT &gt; 2 times the upper limit of normal at baseline, in the absence of&#xD;
             heparin.&#xD;
&#xD;
          -  International Normalized Ratio (INR) &gt;1.6 at baseline in the absence of warfarin.&#xD;
&#xD;
          -  Known clinical site of bleeding or predisposition to bleeding (e.g., GI bleed,&#xD;
             hematuria, hemorrhagic CVA,retroperitoneal hematoma, diabetic retinopathy, hemorrhagic&#xD;
             pericardial effusion, or hemorrhagic pleural effusion. Patients who have a known&#xD;
             clinical site of bleeding may be enrolled if the investigator deems the risk of&#xD;
             continued thrombosis to outweigh the potential bleeding risk.&#xD;
&#xD;
          -  Any patient who has received any investigational medication within 30 days prior to&#xD;
             the first dose of study medication or who is scheduled to receive an investigational&#xD;
             drug other than Argatroban during the course of the study.&#xD;
&#xD;
          -  Known hypersensitivity to Argatroban or chemically related compounds.&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant (positive serum beta-HCG), breast&#xD;
             feeding, or sexually active and not taking adequate contraceptive precautions (e.g.&#xD;
             IUD or oral contraceptives).&#xD;
&#xD;
          -  Any patient receiving a thrombolytic medication (e.g. tPA).&#xD;
&#xD;
          -  Any neonate with a corrected gestational age of &lt; or = 44 weeks and bleeding in the&#xD;
             head (Grade I or above) as determined by head ultrasound.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mattel Children's Hospital at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Illinois</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital, University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Congenital Heart Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies at Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>June 13, 2002</study_first_submitted>
  <study_first_submitted_qc>June 13, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2002</study_first_posted>
  <last_update_submitted>January 10, 2007</last_update_submitted>
  <last_update_submitted_qc>January 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2007</last_update_posted>
  <keyword>heparin-induced thrombocytopenia</keyword>
  <keyword>heparin-induced thrombocytopenia and thrombosis</keyword>
  <keyword>HIT</keyword>
  <keyword>HITTS</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Argatroban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

